Geode Capital Management LLC Has $59.84 Million Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)

Geode Capital Management LLC cut its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 0.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,935,283 shares of the company's stock after selling 20,194 shares during the quarter. Geode Capital Management LLC owned approximately 2.04% of Denali Therapeutics worth $59,835,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its position in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after acquiring an additional 885 shares during the period. KBC Group NV boosted its stake in Denali Therapeutics by 75.8% during the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock worth $129,000 after buying an additional 2,731 shares in the last quarter. AlphaQuest LLC increased its holdings in Denali Therapeutics by 177.1% in the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock valued at $142,000 after buying an additional 4,449 shares during the period. E Fund Management Co. Ltd. raised its stake in shares of Denali Therapeutics by 32.2% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after buying an additional 2,436 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Denali Therapeutics by 128.8% during the 4th quarter. SG Americas Securities LLC now owns 11,003 shares of the company's stock valued at $224,000 after acquiring an additional 6,195 shares in the last quarter. Institutional investors own 92.92% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft initiated coverage on Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price objective on the stock. Cantor Fitzgerald upgraded shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. B. Riley reiterated a "buy" rating and set a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. Robert W. Baird assumed coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price target on the stock. Finally, Oppenheimer dropped their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. One research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of "Buy" and an average price target of $37.57.

Denali Therapeutics Trading Down 0.8 %

Shares of DNLI traded down $0.10 on Tuesday, reaching $13.17. 1,111,450 shares of the company's stock were exchanged, compared to its average volume of 1,081,883. The business has a 50 day moving average price of $16.14 and a two-hundred day moving average price of $21.60. Denali Therapeutics Inc. has a 12 month low of $10.57 and a 12 month high of $33.33. The stock has a market capitalization of $1.91 billion, a P/E ratio of -4.77 and a beta of 1.58.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.08. Equities research analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.